Is mandatory lifestyle intervention before pharmacological obesity management needed?

Many clinical guidelines require a period of lifestyle intervention before initiating obesity management medications. No prospective trial has tested whether this sequence improves outcomes compared with concomitant initiation. The rule likely originated from the duration of behavioural intervention studies and has been reproduced across recommendations without direct validation. Pivotal obesity management drug trials show that pharmacotherapy, not the intensity of lifestyle support, is the primary determinant of weight loss. Early non-response to lifestyle treatment seems to predict future failure and justifies prompt pharmacological escalation; early non-response to pharmacotherapy for obesity may not predict failure and justifies continuation. The same rationale that has led to abandonment of mandatory preoperative lifestyle intervals before metabolic bariatric surgery applies to pharmacotherapy. Recent European Association for the Study of Obesity (2025), American College of Cardiology (2025), Canadian (2025) and Brazilian Association for the Study of Obesity and Metabolic Syndrome (2026) guidelines endorse concomitant initiation of pharmacotherapy and lifestyle intervention. Lifestyle interventions remain essential, but their optimal role is alongside anti-obesity drugs, not as a gatekeeping condition for accessing them.